PARIS--(BUSINESS WIRE)--Stentys (http://www.stentys.com) announced today that its Board of Directors has appointed Dr. Michael Lesh as a Director, effective immediately. Stentys is developing the world’s first next-generation drug-eluting stent for treatment of blocked coronary artery bifurcations so that hundreds of thousands of patients might avoid open-chest surgery.
